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Context:  Women are at increased risk for depressive symptoms during the menopause 
transition. Changes in estradiol secretion and presence of vasomotor symptoms (VMS) 
contribute to perimenopausal depressive symptoms, but links with progesterone have not been 
investigated.  
Objective: To determine whether estradiol variability, ovulatory levels of progesterone, and 
VMS burden are independently associated with perimenopausal depressive symptomatology. 
Design and Intervention: Depressive symptoms, serum levels of estradiol and progesterone, 
and VMS frequency were assessed weekly in an 8-week observational study. Association of 
mood with estradiol variability, ovulatory levels of progesterone, and VMS frequency were 
estimated using generalized estimating equation models. 
Setting:  Academic medical center. 
Patients: Fifty unmedicated perimenopausal women with mild-to-moderate depressive 
symptoms (mean Montgomery-Åsberg Depression Rating Scale [MADRS] score 15.5 ± 5.3). 
Main Outcome Measure: Depressive symptoms (MADRS score). 
Results: During the study, 90.0% of participants had varying estradiol levels, 51.1% had 
ovulatory progesterone levels, and 90% had VMS. Greater estradiol variability and absence of 
progesterone levels consistent with ovulation, but not VMS frequency, are associated with 
higher levels of depressive symptoms (β= 0.11, 95% confidence interval [95%CI] [0.04 to 0.18, 
p=0.001]; β= -2.62 [95%CI -4.52 to -0.71, p=0.007], respectively), after accounting for higher 
BMI, lifetime history of depression, and stressful life events.   
Conclusions: Increasing dysregulation of ovarian hormones, but not VMS, associates with 























perimenopausal mood instability is driven by the underlying hormonal dysregulation of the 
menopause transition involving changes in both estradiol and progesterone. 
 
Precis  
For women with depressed mood during perimenopause, both greater variability of estradiol and 



























Women are at increased risk for mood disturbance across the perimenopause, with 45-68% 
developing depressive symptoms during this reproductive transition.(1) While mood 
disturbances may be severe and constitute a full-blown major depressive episode, 
subsyndromal depressive symptoms are more common and remain important as they cause 
significant distress, impair quality-of-life, and increase health care utilization.(2,3) Identifying 
factors that drive vulnerability for depressive symptoms in the perimenopause helps women and 
their clinicians understand the potential course of depressive symptoms across the menopause 
transition and optimize therapeutic approaches. 
 
Menopause-specific risk factors for the development of perimenopausal depressive symptoms 
include greater variability in serum levels of estradiol, higher and more variable levels of follicle-
stimulating hormone (FSH) and luteinizing hormone (LH), as well as the presence of vasomotor 
symptoms (VMS).(4-10) These associations highlight the potential interactions of changing 
gonadal steroids dynamics with neural mechanisms regulating affect(11-13) and the impact of 
VMS, particularly nocturnal VMS and associated sleep disturbance,(8) in the emergence of 
depressive symptom in the perimenopause. Gonadal steroid changes during the menopause 
transition involve wide excursions in estradiol and less frequent production of progesterone with 
the emergence of anovulation. However, the potential independent impact of progesterone on 
mood, possibly mediated through its neurosteroid metabolite allopregnanolone, has received 
























In the current study, we investigated whether depressive symptom severity in perimenopausal 
women is linked independently with variability of estradiol, production of post-ovulatory levels of 
progesterone, as well as VMS frequency, after accounting for a priori potential confounders 
such as depression history and stressful life events. To achieve this goal, we conducted an 8-
week clinical observational study of 50 perimenopausal women with untreated depressive 
symptoms who completed weekly assessments of mood, serum gonadal steroid levels, and 
VMS. We hypothesized that estradiol variability, progesterone levels consistent with ovulation, 
and VMS frequency would independently predict higher levels of depressive symptoms in 
perimenopausal women. 
 
Materials and Methods 
 
Women with mild to moderate depressive symptoms who were not using psychotropic or 
systemic hormonal medications were enrolled in an 8-week observational study (see Figure 1). 
Throughout the study, participants completed assessments of depressive symptom severity, 
gonadal steroid and gonadotropin assays weekly, together with a daily VMS diary. All subjects 
provided written informed consent for study procedures, which were approved by the Partners 
HealthCare Institutional Review Board and conducted at Massachusetts General Hospital and 
Brigham and Women’s Hospital. 
 
Participants 
Fifty-eight women between the ages of 35–56 years who were perimenopausal, defined by the 
Stages of Reproductive Aging Workshop (STRAW) criteria as being in the early menopause 























transition (>60 days without menses but amenorrhea <12 months in the prior 12 months), 
participated in the study.(14) Participants were recruited from the community through local 
advertising and enrolled if they met eligibility criteria during the period of study accrual. They 
were required to have current mild-to-moderate depressive symptoms, defined as a score 10–
25 on the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS),(15) and/or a 
score >7.7 on the self-rated Kellner Symptom Questionnaire Anger-Hostility subscale.(16) 
Exclusion criteria included women with menstrual irregularities attributable to other conditions 
(pregnancy, lactation, hyperprolactinemia, thyroid dysfunction, polycystic ovarian syndrome, 
hypothalamic amenorrhea), suicidal ideation, a MADRS score >25 indicating severe depression, 
history of severe psychiatric illness (bipolar disorder, psychosis, psychiatric hospitalization or 
suicide attempts within the past 5 years), substance use disorder in the past year, sleep 
disorder diagnosis, and use of antidepressants, systemic hormones, or other centrally active 
medications known to alter mood or VMS. Sleep was monitored at home once using the 




After obtaining written informed consent and confirming eligibility, including assessment of 
depressive symptom severity on the MADRS, blood was drawn to measure serum estradiol, 
progesterone, and FSH at baseline (see Figure 1). Participants also completed a daily VMS 
diary to determine a weekly average of VMS frequency. These assessments were repeated 
thereafter at the weekly visits and during the week between visits for the remainder of the 8-
week study duration. At baseline, current major and minor depression was assessed using the 























study psychiatrists using a clinical interview. In addition, recent stressful life events were self-
reported using Life Experience Survey (LES).(18)  
 
Severity of depressive symptoms 
Severity of depressive symptoms was measured using the clinician-rated 10-item Montgomery 
Åsberg Depression Rating Scale (range 0–60) as described previously.(15) The MADRS has 
good internal consistency (Cronbach’s α=0.82), test-retest reliability (correlation=0.90), and 
validity, and is highly sensitive to changing symptom levels.(19,20) A score of 7–19 and 20–30 
out of 60 is commonly used for identifying mild and moderate depression, respectively. (21)  
 
Hormonal assays 
Serum levels of estradiol were measured by liquid chromatography-mass spectrometry (LC-MS) 
(Mayo Clinic, Rochester, NY), with 10 pg/ml as the lower limit of quantitation.(22,23) The inter-
assay coefficient of variation (CV) for estradiol in this range is 8.6%.(22) Serum progesterone 
was measured by chemiluminescence immunoassays (Abbott Architect ci8200 and Beckman 
Coulter, Fullerton, CA). The lower analytical sensitivities of these assays were 0.1 ng/ml and 
0.08 ng/ml, respectively and both inter-assay CV were ≤10%. Serum FSH was measured by a 
chemiluminescen e immunoassay (Abbott Architect ci8200). The analytical sensitivity was 0.05 
IU/L and the inter-assay CV was estimated ≤10%.  
 
Vasomotor symptoms 
Subjective daily VMS were assessed using a self-report vasomotor symptoms diary, as 
previously described.(24) VMS frequency was then categorized as daytime or nighttime events. 



























This analysis was restricted to the 50 (86.2%) of 58 eligible subjects who completed a minimum 
of 4 consecutive weekly visits and provided complete information on the key predictors and 
outcome. The enrolled sample of 50 did not differ from the 8 ineligible women on key 
demographic and clinical characteristics.   
 
As the data involved multiple within-person observations, we used generalized estimating 
equation (GEE) models to examine the association of depressive symptom severity with 
estradiol variability, progesterone peaks, and VMS frequency, accounting for within-person 
correlation.(25) Visits with estradiol levels below the detection limit (N=83) were given values of 
9 pg/ml. Estradiol was log transformed (ln-estradiol) due to its right-skewed distribution. The CV 
of ln-estradiol was calculated for each subject to integrate the extent to which serum estradiol 
levels varied within each subject over the 8-week period. A progesterone level >6 ng/ml in 
weekly samples was used to define presumed ovulation or its absence in the analysis.(26) VMS 
were analyzed as average daily frequency over the previous week. Therefore, analyses linked 
the time-invariant predictors CV of ln-estradiol and presence of ovulation and the time-variant 
predictor VMS with weekly depressive symptom severity (MADRS) scores describing the same 
week.  
 
We used GEE models to determine the association of severity of depressive symptoms on the 























progesterone levels, VMS frequency) and then each of the following a priori covariates: age, 
race, BMI, marital status, education, lifetime history of depression, and number of stressful life 
events. For each of the univariate models for which the predictor variable was statistically 
significant, multivariate models were developed by adjusting first for the other primary predictors 
and covariates examined that achieved the same significance threshold. Sensitivity analyses 
divided VMS according to daytime and nighttime frequency. In order to examine whether the 
associations were stronger for women who had experienced recent stressful life events or who 
had suffered from a depression previously, the interaction terms stressful life events x estradiol 
variability and stressful life events x presence of presumed ovulation, and lifetime depression x 
estradiol variability and lifetime depression x presence of presumed ovulation were added to the 
multivariate model. 
 
All analyses were adjusted for the number of days between visits (on average a week). Data 
were analyzed using STATA 15 (College Station, Texas), using a p-value of 0.05 as the 




Participant characteristics at baseline 
Baseline characteristics of the 50 subjects in this analysis are reported in Table 1. Briefly, the 
mean age of study participants was 48.4 ± 3.9 years, mean BMI was 27.2 ± 6.7 kg/m2, and the 
majority were either Caucasian (56%) or African American (36%). Menopause status was 
evenly divided between those in the early and late menopause transition. The median FSH and 























148.0) pg/ml, respectively. VMS were reported by 87.5% of participants. The mean baseline 
MADRS score was 15.5 ± 5.3, reflecting mild-to-moderate depressive symptom burden. 
Depressive symptoms were subthreshold for a current major depressive episode in the vast 
majority of participants (87.3%). One-third of participants reported previously experiencing an episode of depression. 
The current episode of mood symptoms developed concurrently or after onset of perimenopause in 
70% of participants and concurrent with or after VMS in 56% of participants. 
 
Course of depressive symptoms during the weekly study visits 
Across the study, MADRS scores remained in the mild-to-moderate depressive range at most 
assessments (10.8 ± 6.5), but there was variability in depressive symptom course between and 
within subjects. The majority of women showed some degree of variability in depressive 
symptom levels during their study participation. MADRS scores varied across the study by 12.7 
± 4.3 (range 3–26), reflecting a wide range of within-person variability in depressive symptom 
levels during follow-up.  
 
Changes in reproductive hormones, menstrual patterns, and vasomotor symptoms during 
follow-up 
As expected for women in the menopause transition, there was substantial between-subject 
variability in menstrual patterns, estradiol, and progesterone profiles during follow-up. The 
majority (72.0%) had some menstrual bleeding or spotting, while a quarter (28.0%) were 
amenorrheic. The coefficient of variation for estradiol ranged from 0–36%. Five (10%) women 
had estradiol levels that were consistently non-detectable throughout the study (<10 pg/ml). Of 
the 45 (90%) women whose estradiol exceeded the detectable threshold at least once, estradiol 























estradiol levels, 51.1% had at least one progesterone level consistent with ovulation. VMS were 
near universal, with a median of 2.1 (IQR 0.9-4.6) VMS/24 hours and only 10.2% of women 
reporting no VMS during follow-up.  
 
Predictors of depressive symptom severity during follow-up 
Associations of depressive symptom severity with estradiol variability, presence of presumed 
ovulation, and VMS frequency are shown in Table 2. Univariate models revealed that greater 
variability in serum estradiol levels was associated with higher levels of depressive symptoms (β 
= 0.11 with 95% confidence interval [CI] [0.02 to 0.21], p=0.02). Univariate models also revealed 
that presence of at least one progesterone level >6 ng/dL was associated with lower depressive 
symptom levels (β = -2.62 [-4.52 to -0.71], p=0.007). VMS frequency was not associated with 
depression symptom severity (β = 0.05 [-0.24 to 0.34], p=0.75). Results were unchanged when 
VMS were analyzed separately by nighttime and daytime (data not shown). Other predictors of 
worse depressive symptoms in univariate models were higher BMI (β = 0.23 [0.08 to 0.37], 
p=0.002), history of depression (β = 3.77 [1.97 to 5.57], p<0.001), and more stressful life events 
(β = 0.31 [0.01 to 0.62], p=0.04), but not the subset of stressful life events that were severe, nor 
age, race, marital status, or education (all p>0.10).   
 
A final multivariate model was built adjusting for BMI, history of depression, and stressful life 
events, covariates that were significantly associated with MADRS scores in univariate models. 
The association of the severity of depressive symptoms with the primary predictors of interest, 
estradiol variability and ovulatory progesterone levels, remained significant (adjusted β = 0.11 
[0.04 to 0.18], p=0.002, and adjusted β = -2.68 [-4.10 to -1.27], p<0.001, respectively, Table 2). 























the relative variability of estradiol and a 2.7-point decrease of the MADRS depression score for 
those who had at least one progesterone level consistent with ovulation relative to those who 
did not. In the same model, all covariates (higher BMI, history of depression, stressful life 
events) remained independent predictors of more severe depressive symptoms (p<0.01). 
Figures 2A and 2B present the marginal means of depressive symptom severity with estradiol 
variability and by the presence of progesterone levels consistent with ovulation, respectively. 
When the adjusted analysis was re-run with the number of presumed ovulatory cycles as a 3-
category variable (1 or 2+ vs. 0), the difference in depressive symptom severity compared with 
the reference group was significant for both the group that had only one (p<0.001) and for those 
who had two or more ovulatory cycles (p=0.013). However, there was no “dose response” 
relationship; those with multiple ovulatory cycles did not have lower levels of depressive 
symptoms than those with one cycle (p=0.36). 
 
The association of estradiol variability and ovulatory progesterone levels with depressive 
symptom severity did not vary by the presence of recent stressful life events nor by a lifetime 




Results of this study show that depression symptom severity during the perimenopause is linked 
to a greater degree of concurrent estradiol variability and the absence of progesterone at levels 
suggesting recent ovulation, but not with the presence of VMS. These findings in women with 
mild-to-moderate depressive symptoms remain after accounting for other factors known to be 























history of major depression, the presence of recent stressful life events, and a higher BMI. Our 
results therefore suggest that perimenopausal mood instability is driven in part by the underlying 
dysregulation of both estradiol and progesterone that is characteristic of the menopause 
transition.  
 
Our analysis focused uniquely on concurrent changes in hormonal profiles in women actively 
experiencing depressive symptoms. To achieve this, we used a repeated-measures approach to 
capture weekly measures of mood, serum gonadal steroid levels, and VMS over an 8-week time 
period. This is in contrast to epidemiologic approaches that have examined reproductive 
hormone levels in women as predictors of subsequent depressive symptoms and mood 
disorders that emerged months or years later.(4,10,7,28) Such approaches contrast with our 
underlying hypothesis that depressive symptoms are caused by concurrent exposure of neural 
circuity linked with mood to highly variable perimenopausal hormone dynamics. During the 
menopause transition, excursions in estradiol and the occurrence of ovulation vary widely both 
within women over time and between women, even among those with relatively comparable 
menstrual patterns.(29,30) This marked variability may explain why depressive symptoms can 
ebb and flow over time during the perimenopause and why some women are susceptible to 
mood disturbance at some, but not all, times over the duration of this transition.  
 
Results of our study highlight the importance and independent roles of both estradiol variability 
and ovulatory levels of progesterone in perimenopausal mood regulation. Numerous studies 
have focused on serum estradiol levels in relation to menopause-related 
depression,(4,10,27,28,31,32) but associations with serum progesterone have not been 























surrounding an ovulatory cycle.(33) It is notable that women are at increased risk for depressive 
symptoms during both the early menopause transition—when ovulation is more common, as 
well as during the late menopause transition—when prolonged amenorrhea and anovulation 
occur more commonly.(1) Therefore, while estradiol variability is more common in the early 
menopause transition and anovulatory cycles are more common in the late menopause 
transition, both occur in either phase of the transition, as does the increased prevalence of 
depressive symptoms. Our population was evenly divided between early and late menopause, 
which gave us the opportunity to examine associations across the menopause transition and a 
wide range of hormone profiles. Of the 90% of women who had at least one detectable estradiol 
level, half had at least one progesterone level consistent with ovulation. Therefore, regardless of 
whether women were in the early or late menopause transition or whether estradiol levels 
fluctuated more or less markedly, depressive symptoms were less severe in our population 
across the 8-week period of observation when progesterone levels indicated recent ovulation.    
 
Consistent with our observation of an inverse relationship between depressive symptoms and 
concurrent exposure to progesterone is the recent finding of an antidepressive effect of the 
progesterone-derived neurosteroid allopregnanolone for treatment of postpartum 
depression,(34) leading to the approval of allopregnanolone by the FDA for postpartum 
depression. As a treatment for another reproductive hormone-associated mood disturbance,(35) 
allopregnanolone’s efficacy for postpartum depression challenges earlier presumptions that 
progestins adversely affect mood. Allopregnanolone may act as a neurosteroid to mediate the 
protective effect of peripheral progesterone on mood through direct inhibition of γ-aminobutyric 
acid (GABA) receptors. However, the relationship of ovarian production of progesterone to 























hormonally sensitive mood disturbance. Collectively, these data illustrate a beneficial effect of 
progesterone and its metabolites on mood in women with hormonally linked mood disturbance.   
 
We observed higher levels of depressive symptoms in association with more marked concurrent 
variability in serum estradiol. Levels of estradiol are known to be more variable during the early 
menopause transition than during the follicular phase of premenopausal menstrual 
cycles.(13,36,37) Variability in estradiol levels during the perimenopause may adversely impact 
mood through mediation of serotonergic and dopaminergic systems within the central nervous 
system since estradiol receptors are widely dispersed across these neuronal networks involved 
in mood-regulating neurotransmission.(38) Alternatively, because estradiol increases 
allopregnanolone,(13) marked variability of estradiol during perimenopause may cause 
fluctuations in allopregnanolone, resulting in failure of the GABAA receptor to regulate overall 
GABA-ergic tone. Dysregulation in GABA-ergic tone may also lead to perturbation of the 
hypothalamic-pituitary-adrenal axis, potentially conferring vulnerability to depression.(13)  
 
Our finding that variability in estradiol is associated with depressed mood is consistent with 
those of some,(4,10,28) but not all,(27,31,32) studies examining associations of serum estradiol 
with depressive symptoms. In contrast to our study, others did not examine estradiol changes in 
relation to concurrent mood, but in relation to subsequent emergence of depression.(4,10,27,28) 
Differences between our and other studies also include the frequency of estradiol sampling. Our 
findings using weekly assessments are generally consistent with others in which estradiol was 
measured more frequently (weekly,(28) monthly,(4,39) or every 6 months (10)) rather than less 
(every 8-12 months (27,31,32)) frequently. Given the changes in estradiol across the 























variability with adverse mood that utilize different estradiol sampling frequencies must be 
interpreted cautiously. Our study population also differs from previous studies that were 
restricted to women with clinically relevant mood disorders,(4,27,28,39) as the vast majority of 
participants in the current study had less severe depressive symptoms that did not constitute a 
major depressive episode. This is important because factors associated with mood disturbance 
during the perimenopause differ between those who have major depressive episodes and those 
with less severe depressive symptoms.(5)  
 
In contrast with previous studies, we did not find stronger associations of estradiol variability (or 
post-ovulatory levels of progesterone) with depressive symptoms in women who recently 
experienced stressful life events (10) nor in those who had a history of major depression.(28) 
Results of our analysis therefore suggest that previous exposure to these independent risk 
factors for depression does not sensitize women to greater depressive symptom burden when 
estradiol varies nor when progesterone levels are low.  
 
VMS, especially when nocturnal, are associated with risk for subthreshold depressive 
symptoms,(1,8,9) but not with clinically relevant depressive disorders in perimenopausal 
women.(1,9,39) We did not observe an association between VMS and depressive symptom 
severity. Our findings are consistent with previous studies in perimenopausal women who had 
variable estradiol levels,(39) but not with other studies in which hypo-estrogenism was 
persistent.(8) It is possible that our sample might be too homogeneous to detect an association 
with VMS as almost 90% of participants reported VMS and only 5% had sustained 























perimenopausal women during a period of hypo-estrogenism, further contributing to the 
complex interrelationships among gonadal steroids, VMS and mood across the perimenopause.  
 
Our study has important strengths, particularly the weekly, concurrent assessment of 
depressive symptoms, gonadal steroids, and VMS in a population whose mental health and 
menopause profile was well-characterized. This approach informs how co-varying menopause-
specific factors contribute to concurrent depressive symptom burden. To date, the majority of 
studies examining hormonal predictors of depressive symptoms have assessed mood, 
reproductive hormones, and VMS as infrequently as every 8–12 months.(27,31,32) While these 
studies powerfully characterize the course and predictors of depressive symptoms over a 
prolonged period of time, they do not provide critical insight into the concurrent relationship 
between real-time reproductive hormone dynamics and depressive symptom levels during this 
dynamic phase of a woman’s life, as our design achieves. Another strength is that estradiol was 
assayed using the gold-standard LC/MS, which has improved reliability over immunoassays in 
the low estradiol range.(40)  
 
Limitations in our study include inherent limitations of any observational study; namely, data 
interpretation is confined to associations rather than causal relationships. While frequent, our 
assessments were weekly, reducing our ability to capture all occurring ovulatory cycles based 
on progesterone levels. However this would have biased any association toward the null, 
thereby limiting our ability to detect an association. Because all analyses were adjusted for time 
between assessments, any between- and within-participant variation due to variable time 
























In summary, we observed that a more optimal concurrent mood state is present when cycles 
are ovulatory and have less variability in estradiol; conversely, greater depressive symptom 
burden is present during anovulatory periods when progesterone is low and estradiol is 
especially variable. Therefore, regardless of whether women are in the early or late menopause 
transition, the highly variable and unpredictable reproductive hormone dynamics during the 
perimenopause explain, at least in part, the variability in depressive symptoms even within an 
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Continuous measures are reported as mean ± standard deviation or in case of non-normal 
distribution as median and interquartile range (IQR). Categorical are presented as number of 
events with percent. 
FSH denotes follicle stimulating hormone; MADRS denotes Montgomery-Åsberg Depression 
Rating Scale; VMS denotes vasomotor symptoms; MDE denotes major depressive episode; 
MDD denotes major depressive disorder. Early and late menopause transition were defined 























a n=49 women with baseline serum  
b n=39 women with detectable estradiol levels 
c n=45 women who had at least one detectable estradiol level 
d n=48 women who completed baseline VMS diary  
e n=49 women who completed at least one VMS diary 
f n=39 women whose VMS were distinguishable as occurring during the night 
g n=37 women whose VMS were distinguishable as occurring during the day 




Associations of estradiol variability, ovulatory progesterone, and vasomotor symptoms 
with severity of depressive symptoms in 50 perimenopausal women with mild-to-
moderate depressive symptoms 
 
Legend 
Estimates are B-coefficients determined by generalized estimating equation analyses. All 
models were adjusted for the number of days between study visits. Severity of depressive 
symptoms was assessed by the Montgomery-Asberg Depression Rating Scale (MADRS).  





























Figure shows data sampling of 50 perimenopausal women during the 8 week study period. 
At every visit the severity of depressive symptoms (Montgomery-Asberg Depression Rating 
Scale [MADRS]) was assessed for the preceding 7 days and blood was drawn in order to 
determine estradiol and progesterone levels. Additionally, every participant reported the 





























Predicted depressive symptom severity by A) variability in serum levels of estradiol 
and by B) detection or not of serum progesterone level indicating recent ovulation 
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